SCHEMBL23927508

SCHEMBL23927508

Cc1ccc(/C=C/C(=O)O)cc1-c1ccnc(N)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.43
RXRA P19793 2/20 0.42
NR4A2 P43354 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
P4HTM Q9NXG6 1/20 0.40
KDM4E B2RXH2 5/20 0.40
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
MAPK1 P28482 2/20 0.40
GAA P10253 2/20 0.40
KMT2A Q03164 2/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA3 P07451 2/20 0.40
CA4 P22748 2/20 0.40
CA6 P23280 2/20 0.40
CA5A P35218 2/20 0.40
CA7 P43166 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22272736 0.86 TTR (0.46) KDM4EALDH1A1GAAKMT2ACA12
SCHEMBL18989499 0.79 NPSR1 (0.54) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL18989859 0.79 NPSR1 (0.54) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL8310796 0.73 NPSR1 (0.54) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL8310794 0.73 NPSR1 (0.54) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL584596 0.70 KDM4E (0.58) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL111230 0.70 KDM4E (0.58) NPSR1P4HTMKDM4EHSD17B10ALDH1A1
SCHEMBL5209241 0.70 NPSR1 (0.49) PTPN11RXRANR4A2NPSR1KDM4E
SCHEMBL5209240 0.70 NPSR1 (0.49) PTPN11RXRANR4A2NPSR1KDM4E
SCHEMBL21859672 0.70 ABL1 (0.62) KDM4EKMT2AMEN1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3901147-B1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2023-11-22 EP disclosed
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2023-01-26 US disclosed
CN-113166116-B Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2022-12-27 CN disclosed
EP-3901147-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF Beijing Scitech-MQ Pharmaceuticals Limited (CN) 2021-10-27 EP disclosed
CN-113166116-A Amido bridged heterocyclic compound, and composition and application thereof 北京赛特明强医药科技有限公司 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026425-A1 ACYLAMINO BRIDGED HETEROCYCLIC COMPOUND, AND COMPOSITION AND APPLICATION THEREOF RIPK1, RIPK3, RIPK4 PTPN11 1315/4885RXRA 984/4885NR4A2 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.